• Citer

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

par André, Thierry;Lonardi, Sara;Wong, Ka Yeung Mark;Lenz, Heinz-Josef;Gelsomino, Fabio;Aglietta, Massimo;Morse, Michael Andew;Van Cutsem, Eric;McDermott, Ray;Hill, Andrew;Sawyer, Michael M.B.;Hendlisz, Alain ;Neyns, Bart;Abdullaev, Sandzhar;Memaj, Arteid;Lei, Ming;Dixon, Matthew;Kopetz, Scott;Overman, Michael James
Référence Annals of oncology
Publication Publié, 2022

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
Auteur:	André, Thierry; Lonardi, Sara; Wong, Ka Yeung Mark; Lenz, Heinz-Josef; Gelsomino, Fabio; Aglietta, Massimo; Morse, Michael Andew; Van Cutsem, Eric; McDermott, Ray; Hill, Andrew; Sawyer, Michael M.B.; Hendlisz, Alain; Neyns, Bart; Abdullaev, Sandzhar; Memaj, Arteid; Lei, Ming; Dixon, Matthew; Kopetz, Scott; Overman, Michael James
Informations sur la publication:	Annals of oncology
Statut de publication:	Publié, 2022
Sujet CREF:	Cancérologie
	Hématologie
Mots-clés:	colorectal cancer
	immune checkpoint inhibitor
	ipilimumab
	metastatic
	MSI-H/dMMR
	nivolumab
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1016/j.annonc.2022.06.008
	info:pii/S0923753422017379
	info:scp/85135508049
	info:pmid/35764271